good luck holders - orphan diseases drugs are hot and there...

good luck holders - orphan diseases drugs are hot and there hasnt been any big breakthroughs in renal medicine in a long time. OD average drug price is around $100k USD per patient per year in areas of unmet clinical need so big pharma will be watching close....very close.

While only a small trial you can expect that any further trials (hopefully a pivotal p3 after this) will also be small which means that DXB could go solo without having to partner it out as trials costs will be modest. A lot of future value can be potentially kept within DXB if this comes out successful.

hard to put a MC on this - NEU is fully funded p3 orphan and around 150 mill mc then you have PAR which hasnt even started P3 in OA and is closer to $800 mill. Ill take anywhere in between....